Cilostazol is a phosphodiesterase III inhibitor that has been shown to be effective for treatment of symptomatic intermittent claudication. It is generally well tolerated, but is contraindicated in patients with severe heart failure because of the potential detrimental effects demonstrated by other agents in the same class. Additional studies are required to examine the long-term benefits of cilostazol therapy.